Skip to main content

Advertisement

Table 3 Biomarker levels of patients in the progression and non-progression groups at ACL reconstruction (baseline)

From: Prediction of progression of damage to articular cartilage 2 years after anterior cruciate ligament reconstruction: use of aggrecan and type II collagen biomarkers in a retrospective observational study

Variables   Total (n = 62) Progression group (n = 15) Non-progression group (n = 47) p value
C2C (ng/ml) Median (IQR) 9.8 (5.8–13.8) 8.8 (5.6–11.8) 10.4 (6.1–14.3) 0.282
Δdi-C6S (nmol/ml) Median (IQR) 69.6 (54.9–95.1) 53.4 (50.9–69.4) 73.5 (60.7–99.9) 0.004
Δdi-C4S (nmol/ml) Median (IQR) 17.1 (14.2–21.6) 16.3 (14.8–17.8) 18.0 (14.2–23.0) 0.170
KS (μg/ml) Median (IQR) 11.6 (9.4–15.6) 9.9 (8.3–11.4) 11.9 (10.0–16.0) 0.021
C2C/KS ratio Median (IQR) 0.71 (0.51–1.2) 0.67 (0.52–1.2) 0.75 (0.51–1.2) 0.928
C6S/C4S ratio Median (IQR) 4.2 (3.6–4.9) 3.9 (3.2–4.4) 4.4 (3.7–5.2) 0.028
  1. Progression group, patients with an increase (between baseline and follow-up) in the number of high-grade cartilage lesions (Outerbridge grades III and IV) by one score in any of the six compartments; Non-progression group, patients with no increase in the number of high-grade cartilage lesions; IQR interquartile range. P < 0.05 was considered statistically significant